Amber Therapeutics Raises $100M for Closed-Loop Neuromodulation Implant for Urinary Incontinence

1. Funding: Amber Therapeutics has secured a $100 million series A funding round to accelerate the development of its closed-loop neuromodulation implant for urinary incontinence.
2. Device: The implant targets the pelvic pudendal nerve to boost sphincter and pelvic floor muscle function and suppress bladder wall contractions, addressing both stress and urge urinary incontinence.
3. Clinical Results: Preliminary results from the first-in-human trial showed that four out of five participants reported complete resolution of mixed incontinence episodes.
4. Investors: The funding round was led by New Enterprise Associates and joined by F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises, and 8VC.
5. Future Plans: Amber Therapeutics plans to launch new pilot studies in Europe and a pivotal trial in the U.S. to achieve regulatory approval.
6. Market Potential: The company estimates that 40 million women in the U.S. have incontinence symptoms, with only 16 million currently receiving any type of therapy.
7. Innovative Approach: Amber's adaptive approach both stimulates the nerve and observes the body's response to regulate bladder function, making it a potential game-changer in the treatment of urinary incontinence.